OpGen, which is acquiring Curetis, said that combined revenue for both companies would have been about $6 million in 2019 had the deal been completed last year.
The immune sequencing firm announced preliminary full-year 2019 revenues in the range of $84 million to $85 million, an increase of approximately 52 percent.
Natera discussed its cancer and transplant rejection testing businesses, while Exact Sciences explained how it will benefit from its Genomic Health acquisition.
On Monday Qiagen reiterated its preliminary 2019 earnings figures and addressed an investor's wrath, while Guardant Health highlighted its cancer testing plans.
Invitae estimated that in 2020 it would accession more than 725,000 samples and bring in more than $330 million in revenue, slightly above current Wall Street projections.
Total revenues of $36.6 million include product and service revenues, which are expected to be about $33.6 million and would be a 42 percent increase year over year.
